Telithromycin

Generic Name
Telithromycin
Brand Names
Ketek
Drug Type
Small Molecule
Chemical Formula
C43H65N5O10
CAS Number
191114-48-4
Unique Ingredient Identifier
KI8H7H19WL
Background

Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.

Indication

临床主要用于敏感菌所致的呼吸道感染,包括社区获得性肺炎、慢性支气管炎、急性上颌窦咽炎及扁桃体炎。

Associated Conditions
Mild community-acquired pneumonia, Moderate Community acquired pneumonia
Associated Therapies
-

Telithromycin in Respiratory Tract Infections

Phase 4
Completed
Conditions
First Posted Date
2005-12-02
Last Posted Date
2009-09-25
Lead Sponsor
Sanofi
Registration Number
NCT00261105

Outpatient Registry Trial of Respiratory Tract Infections in Adults

First Posted Date
2005-10-28
Last Posted Date
2015-07-28
Lead Sponsor
CPL Associates
Registration Number
NCT00245453
Locations
🇺🇸

Western Kentucky Pulmonary Clinic, Louisville, Kentucky, United States

🇺🇸

Northshore Research Associates, Slidell, Louisiana, United States

Study to Measure the Impact of Antibiotics on Bacterial Flora in Adults With Acute Sinusitis

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2005-10-28
Last Posted Date
2007-10-31
Lead Sponsor
CPL Associates
Target Recruit Count
192
Registration Number
NCT00245440
Locations
🇺🇸

Southeastern Researchs Associates,Inc., Taylors, South Carolina, United States

Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days

Phase 4
Terminated
Conditions
First Posted Date
2005-10-12
Last Posted Date
2011-01-11
Lead Sponsor
Sanofi
Target Recruit Count
110
Registration Number
NCT00237445
Locations
🇺🇸

Sanofi-Aventis, Bridgewater, New Jersey, United States

CHOOSE : Telithromycin, Acute Bacterial Sinusitis

Phase 4
Completed
Conditions
First Posted Date
2005-09-15
Last Posted Date
2009-09-25
Lead Sponsor
Sanofi
Target Recruit Count
298
Registration Number
NCT00174694

KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections

First Posted Date
2005-08-22
Last Posted Date
2009-08-27
Lead Sponsor
Sanofi
Target Recruit Count
2051
Registration Number
NCT00132951
Locations
🇨🇦

Sanofi-Aventis Administrative Office, Québec, Canada

PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis

Phase 4
Completed
Conditions
First Posted Date
2005-08-22
Last Posted Date
2011-06-08
Lead Sponsor
Sanofi
Target Recruit Count
5660
Registration Number
NCT00132938
Locations
🇹🇷

Sanofi-Aventis, Istanbul, Turkey

© Copyright 2024. All Rights Reserved by MedPath